MedPath

Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

Phase 3
Completed
Conditions
Episodic Migraine
Interventions
Registration Number
NCT03939312
Lead Sponsor
Allergan
Brief Summary

The purpose of this study is to evaluate the safety and tolerability of atogepant 60 mg once a day for the prevention of migraine in participants with episodic migraine.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
685
Inclusion Criteria
  • Written informed consent and participant privacy information (eg, written authorization for use and release of health and research study information) obtained from the participant prior to initiation of any study-specific procedures.
  • Participants must be using a medically acceptable and effective method of birth control during the course of the entire study.
  • Eligible participants who completed the double-blind treatment period (Visit 7) and the follow-up period (Visit 8), if applicable, depending on the timing of study initiation, of Study 3101-301-002 (NCT03777059) without significant protocol deviations (eg, noncompliance to protocol-required procedures).
Exclusion Criteria
  • Female participant is pregnant, planning to become pregnant during the course of the study, or currently lactating. Women of childbearing potential must have a negative urine pregnancy test at Visit 1.
  • Hypertension as defined by sitting systolic BP > 160 mm Hg or sitting diastolic BP > 100 mm Hg at Visit 1.
  • Participants with clinically significant hematologic, endocrine, cardiovascular, pulmonary, renal, hepatic, gastrointestinal, or neurologic disease.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Atogepant 60 mgAtogepantParticipants received atogepant 60 mg, orally, once daily (QD) for up to 40 weeks.
Primary Outcome Measures
NameTimeMethod
Percentage of Participants With at Least 1 Treatment-Emergent Adverse Event and Treatment-Emergent Serious Adverse Event (TEAEs/TESAEs)From dose of study drug until 30 days following last dose of study drug (up to approximately Week 44)

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants With Potentially Clinically Significant (PCS) Electrocardiograms (ECGs) Findings as Assessed by the InvestigatorUp to Week 40

12-lead ECGs were performed at select study visits. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.

Percentage of Participants With Potentially Clinically Significant (PCS) Vital Sign Measurements as Assessed by the InvestigatorUp to Week 44

PCS postbaseline vital sign values are summarized for categories: systolic and diastolic blood pressures \[sitting and standing\], pulse rate \[sitting and standing\], respiratory rate, temperature, weight. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.

Number of Participants With Suicidal Ideation and Behaviour Using 5-Point Scale of Columbia-Suicide Severity Rating Scale (C-SSRS)OL Treatment Period: Up to Week 40; Safety Follow-up Period: Week 44

C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. Suicidal ideation: Minimum total score 1, maximum total score 5; higher total scores indicate more suicidal ideation. Suicidal behavior: Minimum total score 0, maximum total score 4; higher total scores indicate more suicidal behavior.

Percentage of Participants With Potentially Clinically Significant (PCS) Laboratory Values as Assessed by the InvestigatorUp to Week 44

Clinical laboratory test values are considered PCS if they meet either the lower-limit or higher-limit PCS criteria defined in the categories below. Percentage of participants with PCS laboratory values are summarized for chemistry, hematology, and urinalysis. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during post-baseline are reported.

Trial Locations

Locations (107)

Pediatric and Adolescent NeuroDevelopmental Associates (PANDA) Neurology

🇺🇸

Atlanta, Georgia, United States

Preferred Primary Care Physicians

🇺🇸

Pittsburgh, Pennsylvania, United States

Neuro Pain Medical Center

🇺🇸

Fresno, California, United States

Arkansas Clinical Research

🇺🇸

Little Rock, Arkansas, United States

New England Institute for Clinical Research

🇺🇸

Stamford, Connecticut, United States

Neurology Offices of South Florida

🇺🇸

Boca Raton, Florida, United States

Pharmasite Research, Inc.

🇺🇸

Baltimore, Maryland, United States

Deaconess Clinic - Gateway Health Center

🇺🇸

Newburgh, Indiana, United States

CTI Clinical Research Center

🇺🇸

Cincinnati, Ohio, United States

Synexus Clinical Research, Inc

🇺🇸

San Antonio, Texas, United States

Clinical Research Institute

🇺🇸

Minneapolis, Minnesota, United States

Clinical Trials of Texas

🇺🇸

San Antonio, Texas, United States

Synexus Clinical Research US, Inc.

🇺🇸

Akron, Ohio, United States

Grossmont Center for Clinical Research

🇺🇸

La Mesa, California, United States

Paradigm Clinical Research Centers, Inc

🇺🇸

La Mesa, California, United States

California Headache and Balance Center

🇺🇸

Fresno, California, United States

Torrance Clinical Research Institute, Inc.

🇺🇸

Lomita, California, United States

Pharmacology Research Institute

🇺🇸

Newport Beach, California, United States

Long Beach Clinical Trials Services

🇺🇸

Long Beach, California, United States

Newport Beach Clinical Research Associates

🇺🇸

Newport Beach, California, United States

Excell Research, Inc.

🇺🇸

Oceanside, California, United States

George J. Rederich, M.D. Inc.

🇺🇸

Redondo Beach, California, United States

Rancho Cucamonga Clinical Trials

🇺🇸

Rancho Cucamonga, California, United States

California Neuroscience Research

🇺🇸

Sherman Oaks, California, United States

Neurotrials Research

🇺🇸

Atlanta, Georgia, United States

Meridian Clinical Research, LLC

🇺🇸

Savannah, Georgia, United States

Diamond Headache Clinic Ltd

🇺🇸

Chicago, Illinois, United States

JWM Neurology

🇺🇸

Indianapolis, Indiana, United States

PMG Research, Inc. d/b/a PMG Research of McFarland Clinic

🇺🇸

Ames, Iowa, United States

StudyMetrix Research

🇺🇸

Saint Peters, Missouri, United States

Clinvest Research LLC

🇺🇸

Springfield, Missouri, United States

Dent Neurosciences Research Center

🇺🇸

Amherst, New York, United States

PMG Research of Charlotte, LLC

🇺🇸

Charlotte, North Carolina, United States

Raleigh Neurology Associates, P.A.

🇺🇸

Raleigh, North Carolina, United States

PMG Research of Raleigh, LLC

🇺🇸

Raleigh, North Carolina, United States

PMG Research of Rocky Mount, LLC

🇺🇸

Rocky Mount, North Carolina, United States

Wilmington Health, PLLC

🇺🇸

Wilmington, North Carolina, United States

Patient Priority Clinical Sites

🇺🇸

Cincinnati, Ohio, United States

Aventiv Research Inc

🇺🇸

Columbus, Ohio, United States

Ohio Clinical Research, LLC

🇺🇸

Lyndhurst, Ohio, United States

Lynn Institute of Norman

🇺🇸

Norman, Oklahoma, United States

Tulsa Clinical Research

🇺🇸

Tulsa, Oklahoma, United States

Preferred Primary Care Physicians, Jacob Murphy

🇺🇸

Uniontown, Pennsylvania, United States

Frontier Clinical Research, LLC

🇺🇸

Smithfield, Pennsylvania, United States

Abington Neurological Associates

🇺🇸

Willow Grove, Pennsylvania, United States

Ocean State Clinical Research Partners

🇺🇸

Lincoln, Rhode Island, United States

UT Southwestern Medical Center

🇺🇸

Dallas, Texas, United States

Centex Studies, Inc.

🇺🇸

Houston, Texas, United States

Ventavia Research Group

🇺🇸

Fort Worth, Texas, United States

Protenium Clinical Research

🇺🇸

Hurst, Texas, United States

ClinPoint Trials

🇺🇸

Waxahachie, Texas, United States

Puget Sound Neurology

🇺🇸

Tacoma, Washington, United States

Sentara Neruology Specialists

🇺🇸

Virginia Beach, Virginia, United States

Northwest Clinical Research Center

🇺🇸

Bellevue, Washington, United States

Heartland Research Associates, LLC

🇺🇸

Newton, Kansas, United States

Collective Medical Research

🇺🇸

Prairie Village, Kansas, United States

Colorado Neurological Institute

🇺🇸

Englewood, Colorado, United States

Colorado Springs Neurological Associates

🇺🇸

Colorado Springs, Colorado, United States

Central Phoenix Medical Clinic

🇺🇸

Phoenix, Arizona, United States

Optimus Medical Group

🇺🇸

San Francisco, California, United States

Synexus-US

🇺🇸

Salt Lake City, Utah, United States

Med Center Medical Clinic

🇺🇸

Carmichael, California, United States

Alea Research

🇺🇸

Phoenix, Arizona, United States

Desert Valley Research

🇺🇸

Redlands, California, United States

Alpine Clinical Research Center

🇺🇸

Boulder, Colorado, United States

Sarasota Memorial Hospital Clinical Research Center

🇺🇸

Sarasota, Florida, United States

College Park Family Care Center

🇺🇸

Overland Park, Kansas, United States

John R. Graham Headache Center Brigham and Women's Faulkner Hospital

🇺🇸

Boston, Massachusetts, United States

BTC of New Bedford

🇺🇸

New Bedford, Massachusetts, United States

The Headache Center

🇺🇸

Ridgeland, Mississippi, United States

University of Cincinnati

🇺🇸

Cincinnati, Ohio, United States

New Horizons Clinical Research

🇺🇸

Cincinnati, Ohio, United States

OK Clinical Research, LLC

🇺🇸

Edmond, Oklahoma, United States

Highland Clinical Research

🇺🇸

Salt Lake City, Utah, United States

Health Research of Hampton Roads

🇺🇸

Newport News, Virginia, United States

Charlottesville Medical Research

🇺🇸

Charlottesville, Virginia, United States

Eastside Therapeutic Resource and Core Clinical Research

🇺🇸

Everett, Washington, United States

Primary Care Associates/Synexus Clinical

🇺🇸

Anderson, South Carolina, United States

Well Pharma Medical Research, Corp

🇺🇸

Miami, Florida, United States

ClinSearch

🇺🇸

Chattanooga, Tennessee, United States

Aventura Neurological Associates

🇺🇸

Aventura, Florida, United States

Orange Grove Family Practice

🇺🇸

Tucson, Arizona, United States

Bio Behavioral Health

🇺🇸

Toms River, New Jersey, United States

Principals Research Group

🇺🇸

Hot Springs, Arkansas, United States

Meridien Research

🇺🇸

Saint Petersburg, Florida, United States

Westside Center for Clinical Research

🇺🇸

Jacksonville, Florida, United States

Holston Medical Group

🇺🇸

Kingsport, Tennessee, United States

J. Lewis Research, Inc. / Foothill Family Clinic South

🇺🇸

Salt Lake City, Utah, United States

J. Lewis Research, Inc.

🇺🇸

South Jordan, Utah, United States

Clinical Neuroscience Solutions

🇺🇸

Orlando, Florida, United States

University of South Florida

🇺🇸

Tampa, Florida, United States

Sarkis Clinical Trials- Gainesville

🇺🇸

Gainesville, Florida, United States

Axiom Clinical Research of Florida

🇺🇸

Tampa, Florida, United States

Heartland Research Associates, LLC - An AMR Company

🇺🇸

Wichita, Kansas, United States

DelRicht Research

🇺🇸

New Orleans, Louisiana, United States

Albuquerque Clinical Trials

🇺🇸

Albuquerque, New Mexico, United States

Piedmont Medical Research of Winston-Salem

🇺🇸

Winston-Salem, North Carolina, United States

Clinical Trials of South Carolina

🇺🇸

Charleston, South Carolina, United States

Psychiatry & Psychotherapy Partners Austin

🇺🇸

Austin, Texas, United States

Tekton Research

🇺🇸

Austin, Texas, United States

National Clinical Research, Inc

🇺🇸

Richmond, Virginia, United States

Baptist Health Center for Clinical Research

🇺🇸

Little Rock, Arkansas, United States

Clinical Neuroscience Solutions, Inc.

🇺🇸

Memphis, Tennessee, United States

Neurology Associates of Ormond Beach

🇺🇸

Ormond Beach, Florida, United States

Partners in Clinical Research, LLC

🇺🇸

Cumberland, Rhode Island, United States

Hillcrest Family Practice

🇺🇸

Simpsonville, South Carolina, United States

Thomas Jefferson University

🇺🇸

Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath